Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.53 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.53 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.53 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.51 |
| ▸ | REN | P00797 | 5/20 | 0.50 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 2/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | KDM5A | P29375 | 1/20 | 0.49 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.49 |
| ▸ | TACR1 | P25103 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | TFPI | P10646 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22018606 | 0.92 | OPRD1 (0.48) | KEAP1RENNMUR2F2OPRD1 | |
| SCHEMBL30933098 | 0.91 | REN (0.53) | KEAP1RENNMUR2F2OPRD1 | |
| SCHEMBL29308367 | 0.91 | BCL2L1 (0.48) | KEAP1F2OPRD1TFPI | |
| SCHEMBL22922808 | 0.91 | APLNR (0.49) | KDM1AMAPK8MAPK9MAPK10REN | |
| SCHEMBL22019459 | 0.91 | APLNR (0.49) | KDM1AMAPK8MAPK9MAPK10REN | |
| SCHEMBL22018348 | 0.91 | APLNR (0.49) | KDM1AMAPK8MAPK9MAPK10REN | |
| SCHEMBL22019143 | 0.90 | OPRD1 (0.56) | KEAP1F2OPRD1 | |
| SCHEMBL22018355 | 0.90 | MAPK8 (0.50) | KDM1AMAPK8MAPK9MAPK10KEAP1 | |
| SCHEMBL30933101 | 0.89 | REN (0.54) | RENNMUR2F2OPRD1 | |
| SCHEMBL22380787 | 0.89 | APLNR (0.47) | KDM1AMAPK8MAPK9MAPK10REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312648-A1 | PEPTIDES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE DISEASES | YUYU PHARMA, INC. (KR) | 2023-10-05 | — | — | US | disclosed |
| US-20200270306-A1 | PEPTIDES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE DISEASES | YUYU PHARMA, INC. (KR) | 2020-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312648-A1 | PEPTIDES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE DISEASES | VIP, IAPP, SCTR | KDM1A 4761/4885MAPK8 2678/4885MAPK9 1074/4885 |
| US-20200270306-A1 | PEPTIDES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE DISEASES | VIP, IAPP, SCTR | KDM1A 4761/4885MAPK8 2678/4885MAPK9 1074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.